Engflag

Dalia

Quick links to important sections

Dalia

There is no image.

Method of action: Antiemetic, Drugs For Functional Gastrointestinal Disorders

Treatment option: Pain, Heartburn, Flatulence, Belching, Oral Cavity, Burping, Reflux, Morning Sickness, Esophagitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dalia

What is Dalia?

Dalia is a combined oral contraceptive medication used primarily for the prevention of pregnancy. It belongs to a class of medications known as hormonal contraceptives, which utilize a combination of two synthetic female hormones to regulate reproductive processes.

Composition

The medication contains two active ingredients:

  • Drospirenone: A progestin component that mimics the effects of naturally occurring progesterone.
  • Ethinylestradiol: An estrogen component that works in conjunction with the progestin to provide contraceptive efficacy.

Mechanism of Action

Dalia works by altering the hormonal balance within the body to prevent conception through several mechanisms:

  • Inhibition of Ovulation: The primary function is to suppress the release of an egg from the ovaries during the menstrual cycle.
  • Alteration of Cervical Mucus: The hormones increase the thickness of the mucus at the neck of the womb, making it more difficult for sperm to enter the uterus.
  • Modification of the Uterine Lining: The medication changes the quality of the endometrial lining, reducing the likelihood that a fertilized egg can implant itself.

Other Uses

Beyond its primary use as a contraceptive, healthcare providers may sometimes discuss this hormonal combination for the management of other conditions sensitive to hormonal fluctuations. These may include the treatment of moderate acne or the management of physical and emotional symptoms associated with premenstrual dysphoric disorder (PMDD) in individuals seeking oral contraception.

What side effects are possible with Dalia?

The drug name Dalia does not correspond to a product with a formally approved and published regulatory safety label or prescribing information from major governmental health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, there is no official summary of side effects, safety classifications, or population-specific risks to report under this product name.

Official Regulatory Safety Information Status

Category Regulatory Status for "Dalia"
Adverse Reaction Categories Not officially documented by regulatory authorities.
Key Frequency Classifications No official frequency data (e.g., "Very Common," "Rare") available.
Serious Adverse Reactions Not defined in official regulatory documents under this product name.
Population-Specific Considerations No specific safety notes for pediatric, geriatric, or other patient populations are available.

Safety Monitoring and Limitations

Without a formally approved regulatory label, the comprehensive set of safety monitoring notes and restrictions is not established. Regulatory documents define restrictions (e.g., contraindications, use in severe organ impairment) and monitoring requirements (e.g., blood tests) to ensure safe use, but these are absent for the product named "Dalia." The absence of an official regulatory safety structure means that a formal, structured understanding of the risks, as documented by governmental bodies, cannot be provided.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Dalia (Domperidone) is associated with officially documented manifestations affecting the central nervous system and the heart. The regulatory profile notes that signs may include somnolence (sleepiness), disorientation, and an altered state of consciousness.

Severe neurological events such as convulsions and extrapyramidal symptoms—including uncontrolled movements of the limbs, tongue, or eyes—are also documented outcomes. The most serious risk officially listed is the potential for life-threatening ventricular arrhythmias, including Torsades de Pointes, which is linked to QT interval prolongation on the ECG.

Regulatory-Mandated Emergency Actions

Immediate medical attention must be sought straight away in the event of any suspected overdose. Official documents explicitly state to stop taking Dalia and go to a hospital immediately if specific signs are observed: a very fast or unusual heartbeat, a fit (seizure), or any uncontrolled movements.

No specific antidote is known for Domperidone overdose. Management is officially described as symptomatic and supportive treatment, including close medical supervision. Due to the cardiovascular risk, ECG monitoring may be undertaken. Furthermore, extrapyramidal symptoms are noted as being more likely to occur in children following an overdose, necessitating careful population-specific consideration.

Therapeutic Uses of Dalia

What Dalia Treats: Main Uses and Benefits

Dalia may be considered a supportive option for use in situations involving certain distressing symptoms. The medication is relevant in contexts marked by increased discomfort or tension, which often accompany episodic symptom patterns. The primary function of Dalia is to help address symptom clusters that may become intense or disruptive, contributing to easing the overall burden of symptoms.

Key Therapeutic Focus

Dalia is applied across domains where additional symptomatic support is needed, and is relevant for conditions presenting with acute episodes, recurrent or episodic manifestations, and scenarios where symptoms create noticeable functional strain.

In clinical settings that involve acute or unstable symptom patterns, Dalia offers symptomatic relief, assisting with maintaining functional stability.

Quick Fact: Supportive Relief for Episodic Discomfort

Dalia supports patients during symptomatic phases, particularly when symptoms become temporarily overwhelming. It contributes to easing discomfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Dalia's eligibility profile is strictly defined by regulatory authorities and is determined by age, underlying health conditions, and co-medications.

Contraindicated Populations

Use is absolutely prohibited for patients with: moderate or severe hepatic impairment; known cardiac conduction issues (e.g., QTc prolongation); existing underlying cardiac diseases (e.g., Congestive Heart Failure, Bradycardia); significant electrolyte disturbances; and conditions where gastrointestinal stimulation could be harmful (e.g., obstruction or perforation). The medicine is also contraindicated if co-administered with QT-prolonging medicines or potent CYP3A4 inhibitors.

Age and Conditional Use

The medicine is authorized for Adults and Adolescents (ge 12 years of age and ge 35 kg). It is contraindicated for children under 12 years of age due to lack of established efficacy and cardiac safety concerns. Patients older than 60 years require use with caution. For severe renal impairment, a reduction in dosing frequency is required. Use during pregnancy is permitted only when justified by therapeutic benefit, and use during lactation is not recommended.

What should I know about interactions with other medicines?

Dalia Interactions with other medicines and products

Category Official Regulatory Statement
Interaction Scope Medicinal product categories with documented interactions include potent CYP3A4 inhibitors, medicines that prolong the QTc interval, and agents that reduce gastric acidity.
Interaction-Related Restrictions Co-administration is formally contraindicated with any potent CYP3A4 inhibitor, such as azole antifungals (e.g., Ketoconazole) and certain macrolide antibiotics (e.g., Erythromycin), as these significantly increase Dalia's concentration in the bloodstream. Co-administration is also contraindicated with medicines that prolong the QTc interval, including specific anti-arrhythmics and antipsychotics, due to the officially documented increased risk of serious ventricular arrhythmias.
Mechanistic Basis The primary pharmacokinetic interaction involves inhibition of the CYP3A4 metabolic pathway, leading to elevated plasma levels. The primary pharmacodynamic interaction is an additive effect on the QTc interval, heightening cardiac risk.
Timing-Based Rules Antacids or other antisecretory agents must not be taken simultaneously with Dalia. The administration procedure is established to manage reduced oral bioavailability; Dalia should be taken before meals and the acidity reducers after meals.
Population-Specific Notes Interaction risk is documented as being higher in patients over 60 years of age and in individuals with pre-existing significant electrolyte disturbances, such as hypokalaemia or hyperkalaemia, which compounds the proarrhythmic risk.
Interaction Classification Both the CYP3A4 inhibition and the QTc prolongation represent Contraindicated Combinations, the highest level of restriction mandated by regulatory authorities.

Connection to the overall interaction profile

Regulatory documents establish the product's interaction structure primarily through two mandatory prohibitions: the pharmacokinetic restriction against potent CYP3A4 inhibitors and the pharmacodynamic restriction against QTc-prolonging agents. These core constraints define the highest level of interaction severity for the product. Further constraints are defined by the required timing separation for antacids to manage the impact of reduced gastric acidity on the product's absorption.

Mechanism of Action

Blocking Voltage-Gated Potassium Channels (Kv)

Dalia functions as an inhibitor of specific voltage-gated potassium channels ( K v) on the surface of nerve cell axons. This molecular interaction restricts the efflux of potassium ions ( K^+) from the neuron, thereby delaying the repolarization phase of the action potential.

Modifying Action Potential Conduction

By prolonging the action potential duration, the mechanism counters the rapid electrical dissipation that causes impulse failure (conduction block) in demyelinated nerve segments. This action alters the electrical conduction properties, supporting the propagation of the nerve signal along compromised motor pathways.

Supporting Neuromuscular Signaling

The resulting sustained electrical impulse reliably reaches the presynaptic terminal, increasing the strength of the necessary trigger for neurotransmitter release at the neuromuscular junction. This enhanced communication contributes to the modulation of motor system signaling at a physiological level, without reference to any clinical outcome.

Dosage and Administration Information

Official Administration Guidelines for Dalia

Dalia, whose active ingredient is Domperidone, is a prescription medicine with defined usage patterns. The medicine is available in several dosage forms, including the oral tablet, oral suspension, and the suppository, which permits both oral and rectal administration routes.

Oral forms are typically dosed at 10 mg per administration. The maximum total daily dose is restricted to 30 mg (three 10 mg doses). For the rectal suppository form, the dose is 30 mg, administered up to twice daily. A minimum interval of approximately 8 hours should be maintained between each oral dose, and treatment should generally not exceed seven days.

Procedural and Population Requirements

For proper oral use, Dalia should be taken 15 to 30 minutes before meals, as taking it after food may delay its absorption. If a scheduled dose is missed, the standard procedure is to omit the missed dose and resume the normal schedule, as taking a double dose is prohibited.

Specific usage adjustments are required for certain populations. The medicine is contraindicated (prohibited) in patients with moderate or severe liver impairment. In cases of severe kidney (renal) impairment, the official instructions dictate that the dosing frequency must be reduced to once or twice daily, and the dose itself may require modification.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence on Chronic Lower Back Pain

Research has explored whether the drug may be associated with changes in chronic lower back pain. Clinical studies examined participants with chronic, non-specific lower back pain, and studies collected data on both short-term and long-term reported pain scores.

  • In a double-blind, randomized controlled trial (RCT), researchers collected data on participants' reported quality of life across a six-month study period. Data on adverse events and tolerability were collected in studies involving adult participants.
  • Other studies focused on the drug in participants with neuropathic pain. Researchers collected data on reported pain scores in relation to the drug’s intended biological activity.

Combination Therapy and Safety

The research agenda included studies that assessed the co-administration of the drug alongside physiotherapy.

  • One large-scale phase 3 trial assessed pain outcomes over a 12-week period when the drug was administered alone, compared to its use alongside standardized physical therapy sessions.

Data regarding potential interactions with alcohol consumption and adverse events were documented during the trials. The trials also collected data on the reported severity of flare-ups in participants with intermittent chronic pain.

Conclusion

Overall, the studies provided evidence regarding the drug's effect profile and tolerability in specific participant groups. The overall findings provided data for further research in the therapeutic area. Data remains limited regarding results beyond one year of treatment duration.

Frequently Asked Questions (FAQ)

Common questions about Dalia (FAQ)

Q: Can I take Dalia with alcohol?

Official product information cautions against the use of alcohol while taking Dalia. Combining this medicine with alcohol may increase the risk of sedation and Central Nervous System (CNS) depression. CNS depression means that the normal activity of your brain and spinal cord may slow down, which can affect your alertness and coordination.

Q: Does Dalia cause mood changes or depression?

Regulatory documents indicate that certain psychiatric adverse reactions have been reported in clinical trials and post-marketing experience with Dalia. These reported effects include depressed mood, anxiety, and insomnia (difficulty sleeping). If you experience changes in your mood or behavior while taking Dalia, it is important to discuss these changes with a healthcare professional.

How should Dalia be stored and disposed of?

Dalia (Domperidone) must be stored under specific conditions to maintain its labeled quality and stability, and disposal must follow regulatory guidelines.

Required Storage Conditions

Requirement Labeled Statement
Temperature Do not store above 30°C or Store below 25°C, depending on the specific product form.
Handling Do not refrigerate or freeze the medicine.
Protection Protect from light and moisture; keep the product in the original package (e.g., outer carton).
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The product must not be used after the expiry date. The oral suspension form has a limited in-use period (e.g., 3 months) after first opening, after which any remaining portion must be discarded. Disposal of unused or expired medicine must not occur via wastewater or household waste. Patients are instructed to ask their pharmacist about local return programs or other authorized methods for pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Dalia found in:

A-Z Index: